Novartis Healthcare Launches Sequadra Inhaler for Advance Treatment of COPD Patients
Novartis Healthcare Private Limited (NHPL) launched Sequadra Inhaler (indacaterol/glycopyrronium) 110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, […]
